Arbutus Biopharma (ABUS) Accounts Payables (2010 - 2026)

Arbutus Biopharma's Accounts Payables history runs 17 years deep, the most recent figure standing at $4.5 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 63.05% year-over-year to $4.5 million; the TTM figure through Mar 2026 stood at $4.5 million (down 63.05% YoY), while the FY2025 annual figure was $5.5 million, down 27.83% from the prior year.
• Accounts Payables came in at $4.5 million for Q1 2026 at Arbutus Biopharma, down from $5.5 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $16.0 million in Q4 2022 to a low of $4.5 million in Q1 2026.
• A 5-year average of $9.0 million and a median of $8.8 million in 2023 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables jumped 49.35% in 2022 and sank 63.05% in 2026, its largest moves.
• Arbutus Biopharma's Accounts Payables stood at $16.0 million in 2022, then slumped by 35.92% to $10.3 million in 2023, then slipped by 26.36% to $7.6 million in 2024, then slipped by 27.83% to $5.5 million in 2025, then retreated by 18.04% to $4.5 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $4.5 million, $5.5 million, and $4.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison